Skip to main content
SpringerLink
Log in

Somatostatin and Somatostatin Analogues in Human Breast Carcinoma

  • Chapter
Peptides in Oncology II

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 129))

Abstract

Somatostatin is a tetradecapeptide that was initially isolated from the hypothalamus and was found to be an inhibitor of growth hormone (GH) secretion (Brazeau et al. 1973) and, under certain conditions, of prolactin (PRL) release (Kimura et al. 1986). However, the therapeutic use of natural somatostatin is limited by its short half-life and the short duration of its antisecretory effects (Thomas et al. 1991). In order to increase the therapeutic efficacy of the drug, somatostatin analogues with a prolonged half-life have been synthesized (e.g., BIM-23014C, RC160, and SMS201–995).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Bogden AE, Taylor JE, Moreau JP, Coy DH (1990) Treatment of R-3327 prostate tumors with a somatostatin analogue (somatuline) as adjuvant therapy following surgical castration. Cancer Res 50: 2646–2650

    PubMed  CAS  Google Scholar 

  • Brazeau P, Vale W, Burgas R, Ling N, Butscher M, Rivier J, Guillemin R (1973) Hypothalamic polypeptides that inhibit the secretion of immunoreactive pituitary growth hormone. Science 179: 77–79

    Article  PubMed  CAS  Google Scholar 

  • Ciocca DR, Puy LA, Fasoli LC Tello O, Aznar JC, Gago FE, Papa SI, Sonego R (1990) Corticotropin releasing hormone, luteinizing hormone releasing hormone, growth hormone releasing hormone and somatostatin like immunoreactivities in biopsies from breast cancer patients. Breast Cancer Res Treatment 15: 175–184

    Article  CAS  Google Scholar 

  • Fekete M, Wittliff A, Schally AV (1989) Characteristics and distribution of receptors for (D-Trp6)-Luteinizing-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer. J Clin Lab Anal 3: 137–147

    Article  PubMed  CAS  Google Scholar 

  • Foekens JA, Portengen H, van Putten WLJ, Trapman AM, Reubi JC, Alexia-Figusch S, Klijn JGM (1989) Prognostic value of receptors for insulin-like growth factor, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res 49: 7002–7009

    PubMed  CAS  Google Scholar 

  • Foekens JA, van Putten W, Portengen H, Rodenburg CJ, Reubi JC, Berns PM, Henzen-Logmans SC, van der Burg M, Klijn JMG (1990) Prognostic value of pS2 protein and receptors for epidermal growth factor, insulin-like growth factor I and somatostatin in patients with breast and ovarian cancer. J Steroid Biochem Mol Biol 37: 815–821

    Article  PubMed  CAS  Google Scholar 

  • Ghirlanda G, Ucciolo L, Perri F, Almonte L, Bertoli A, Manna R, Frati L, Greco AV (1983) Epidermal growth factor, somatostatin and psoriasis. Lancet i(8): 65

    Google Scholar 

  • Kimura N, Hayafuji C, Konagaya H, Takahashi K (1986) 17 beta-estradiol induces somatostatin ( SRIF) inhibition of prolactin release and regulates SRIF receptors in rat anterior pituitary cells. Endocrinology 119: 1028–1036

    Google Scholar 

  • Klijn JGM, Setyono-Han B, Bakker GH, van der Burg MEL et al. (1990) Growth factor receptor pathway interfering treatment by somatostatin analogs and suramin: preclinical and clinical studies. J Steroid Biochem Mol Biol 37: 1089–1095

    Article  PubMed  CAS  Google Scholar 

  • Krenning EP, Lamberts SWJ, Reubi JC, Kwekkeboom DJ (1991) 111-In octreotide in scintigraphy in oncology. Congress on Sandostatin, Monté-Carlo, p 39

    Google Scholar 

  • Manni A, Boucher AE, Demers LM, Harvey HA, Lipton A, Simmonds MA, Bartholomew M (1989) Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancer. Breast Cancer Res Treat 14: 289–298

    Article  PubMed  CAS  Google Scholar 

  • McGuire WL, Dickson RB, Osborne CK, Salomon D (1988) The role of growth factors in breast cancer. Breast Cancer Res Treat 12: 159–166

    Article  PubMed  CAS  Google Scholar 

  • Morère JF, Cour V, Breau JL, Boaziz C, Basin C, Israël L (1989) Stabilizing effect of BIM23014, a long acting somatostatin analog in 30 cases of advanced breast cancer: a phase II study. Proc Am Soc Clin Oncol 8: abstract 179

    Google Scholar 

  • Murphy WA, Taylor JE, Moreau S, Moreau JP (1990) New octapeptide analogs of somatostatin with enhanced in vitro activity and receptor affinity. 72nd annual meeting of the American endocrine society, Atlanta, GA, June 20–23, 1990, abstract 518, p. 154

    Google Scholar 

  • Murthy KK, Srikant CB, Patel Y (1990) Evidence for multiple protein constituents of the somatostatin receptor in pituitary tumor cells: affinity cross-linking and molecular characterization. Endocrinology 125: 948–956

    Article  Google Scholar 

  • Nelson J, Cremin M, Murphy RF (1989) Synthesis of somatostatin by breast cancer cells and their inhibition by exogenous somatostatin and sandostatin. Br J Cancer 59: 739–742

    Article  PubMed  CAS  Google Scholar 

  • Pagliacci MC, Tognellini R, Grignani F, Nicoletti I (1991) Inhibition of human breast cancer cell (Mcf7) growth in vitro by the somatostatin analog SMS201–995 effects on cell cycle parameters and apoptotic cell death. Endocrinology 129: 255–256

    Article  Google Scholar 

  • Papotti M, Macri L, Bussolati G, Rebi JC (1989) Correlative study on neuroendocrine differentiation and presence of somatostatin receptors in breast carcinomas. Int J Cancer 43: 365–369

    Article  PubMed  CAS  Google Scholar 

  • Prévost G, Gonzalez W, Thomas F (1991 a) La somatostatine et ses analogues dans le traitement du cancer du sein. Cah Cancerol 3: 3–10

    Google Scholar 

  • Prévost G, Foehrlé E, Thomas F, Pihan I, Veber N, Starzec A, Israel L (1991 b) Growth of human breast cancer cells inhibited by the somatostatin analogue BIM23014 (somatuline). Endocrinology 128: 323–330

    Google Scholar 

  • Prévost G, Lanson M, Thomas F, Veber N, Gonzalez W, Beaupain R, Starzec A, Bogden A (1992) Molecular heterogeneity of somatostatin analogue BIM23014C receptors in human breast carcinoma using cross-linking assay. Cancer Res 52: 843–850

    PubMed  Google Scholar 

  • Reubi JC, Torhorst J (1989) The relationship between somatostatin, epidermal growth factor, and steroid hormone receptors in breast cancer. Cancer 64: 1254–1260

    Article  PubMed  CAS  Google Scholar 

  • Reubi JC, Maurer R, von Keder K, Torhost J, Klijn JGM, Lamberts SWJ (1987) Somatostatin receptors in human endocrine tumors. Cancer Res 47: 551–558

    PubMed  CAS  Google Scholar 

  • Reubi JC, Waser B, Foekens JA, Klijn JG, Lamberts SWJ, Laissue J (1990) Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography: relationship to EGF receptor. Int J Cancer 46: 416–420

    Article  PubMed  CAS  Google Scholar 

  • Scambia G, Benedetti Panici P, Baiocchi P, Perrone L, lacobelli S, Mancuso S (1988) Antiproliferative effects of somatostatin and the somatostatin analog SMS201–995 on three human breast cancer cell lines. J Cancer Res Clin Oncol 114: 306–308

    Article  PubMed  CAS  Google Scholar 

  • Setyono-Han B, Henkelman MS, Foekens JA, Klijn JGM (1987) Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells. Cancer Res 47: 1566–1570

    PubMed  CAS  Google Scholar 

  • Stolfi R, Parisi AM, Natoli C, Iacobelli S (1990) Advanced breast cancer: response to somatostatin. Anticancer Res 10: 203–204

    PubMed  CAS  Google Scholar 

  • Srkalovic G, Cai R, Schally A (1990) Evaluation of receptors for somatin in various tumors using different analogs. Endocrinology 70: 661–669

    CAS  Google Scholar 

  • Szende B, Lapis K, Redding W, Srkalovic G, Schally A (1989) Growth inhibition of MTX mammary carcinoma by enhancing programmed cell death (apoptosis) with LH-RH and somatostatin. Breast Cancer Res Treat 14: 307–314

    Article  PubMed  CAS  Google Scholar 

  • Taylor J, Bogden A, Moreau JP, Coy D (1988) In vitro and in vivo inhibition of human small cell lung carcinoma (NCI-H69) growth by a somatostatin analogue. Biochem Biophys Res Commun 153: 81–86

    Article  PubMed  CAS  Google Scholar 

  • Thomas F, Parmar A, Prévost G, Kuhn JM, Moreau JP, Bogden A (1991) Les analogues de la somatostatine en cancérologie. Bull Cancer 78: 693–707

    PubMed  CAS  Google Scholar 

  • Thomas F, Parmar A, Prévost G, Kuhn JM, Moreau JP, Bogden A (1991) Les analogues de la somatostatine en cancérologie. Bull Cancer 78: 693–707

    PubMed  CAS  Google Scholar 

  • Vennin P, Peyrat JP, Bonneterre J, Louchez MM, Harris AG, Demaille A (1989) Effect of the long-acting somatostatin analogue SMS201–995 (sandostatin) in advanced breast cancer. Anticancer Res 9: 153–156

    PubMed  CAS  Google Scholar 

  • Weber C, Merriam L, Koschitzky T, Karp F, Benson M, Logerfo P (1989) Inhibition of growth of human breast carcinomas in vivo by somatostatin analog SMS201–995: treatment of nude mouse xenografts. Surgery 106: 416–422

    PubMed  CAS  Google Scholar 

  • Weckbecker G, Bruns C, Liu R, Tolscsvai L, Pless J (1990) Growth inhibitory effect of SMS201–995 in cell and animal cancer models. Growth factors and their receptors in cancer, Congress of Houston, p 112 (abstract 61)

    Google Scholar 

  • Yamada Y, Post SR, Wang K, Tager HS, Bell GI, Seino S (1992) Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain gastrointestinal tract and kidney. Proc Natl Acad Sci 89: 251–255

    Article  PubMed  CAS  Google Scholar 

  • Yee D, Paik S, Lebovic GS, Marcus RR, Favoni RE, Cullen KJ, Lippman ME, Rosen N (1989) Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol 3: 509–517

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut d’Oncologie Cellulaire et Moléculaire Humaine, 129 route de Stalingrad, 93000, Bobigny, France

    G. Prévost

  2. Service d’Oncologie Médicale, CHU Avicenne, 125 route de Stalingrad, 93000, Bobigny, France

    L. Israel

Authors
  1. G. Prévost
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Israel
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Innere Medizin II: Onkologie — Hämatologie — Endokrinologie — Stoffwechselerkrankungen, Klinikum der Friedrich-Schiller-Universität Jena, Erlanger Allee 101, O-6902, Jena-Lobeda, Germany

    K. Höffken

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Prévost, G., Israel, L. (1993). Somatostatin and Somatostatin Analogues in Human Breast Carcinoma. In: Höffken, K. (eds) Peptides in Oncology II. Recent Results in Cancer Research, vol 129. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-84956-5_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-84956-5_5

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-84958-9

  • Online ISBN: 978-3-642-84956-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation